Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.02EUR
17 Aug 2018
Change (% chg)

€0.02 (+0.02%)
Prev Close
€90.00
Open
€90.00
Day's High
€90.28
Day's Low
€89.58
Volume
408,069
Avg. Vol
571,866
52-wk High
€100.95
52-wk Low
€74.54

Select another date:

Thu, Aug 9 2018

Merck KGaA profit dragged lower by liquid crystal decline, forex

FRANKFURT Germany's Merck KGaA saw adjusted core earnings decline 13.7 percent in the second quarter on lower revenues from liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

Merck KGaA profit dragged lower by liquid crystal decline, forex

FRANKFURT, Aug 9 Germany's Merck KGaA saw adjusted core earnings decline 13.7 percent in the second quarter on lower revenues from liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

Germany's Merck sees performance materials unit turning corner in 2020

FRANKFURT Germany's Merck KGaA said it expects its performance materials business to return to sales and earnings growth after next year as it tackles tough competition from Chinese rivals in the market for liquid crystals for flat-screen televisions.

UPDATE 1-Germany's Merck sees performance materials unit turning corner in 2020

* Decline in liquid crystals to be offset by other business (Adds sales target for unit, divisional CEO comment)

Merck KGaA sees Performance Materials returning to growth after 2019

FRANKFURT, July 3 Germany's Merck KGaA said it aimed to return to earnings growth its Performance Materials business, which makes liquid crystals for flat-screen TVs, after next year as it tackles tough competition from Chinese rivals.

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find a drug-industry partner to share further development costs for one of them.

UPDATE 2-Merck KGaA's lung cancer drugs show promise in early-stage trials

* Shares up 5.2 pct (Adds Merck ruling out enlisting partner for tepotinib development)

Merck KGaA's lung cancer drugs show promise in early-stage trials

FRANKFURT, May 16 Germany's Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping the company's efforts to find drug-industry partners to share further development costs.

Merck KGaA first quarter earnings down on liquid crystals, currencies

FRANKFURT Germany's Merck KGaA saw earnings decline in the first quarter and predicted a drop for the full year, hurt by Chinese competition in liquid crystals used in flat screens and a strong euro weighing on the value of overseas sales.

UPDATE 1-Merck KGaA Q1 earnings down on liquid crystals, currencies

* Strong euro to cause 5-7 percent drag on 2018 EBITDA (Adds detailed guidance, forex effects)

Select another date: